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Introduction: In vivo animal data have shown prothrombin complex concentrate (PCC) to be effective in
preventing bleeding induced by excessive plasma levels of the direct thrombin inhibitor dabigatran. This animal
model studywas designed to determine the risk of thrombosis associated with administration of a PCC (Beriplex
P/N) to reverse dabigatran-induced bleeding.
Materials andmethods:Anesthetized rabbits were treatedwith initial 0, 75, 200 or 450 μg kg-1 dabigatran boluses
followed by continuous infusions to maintain elevated plasma dabigatran levels. At 15 min after the start of
dabigatran administration, PCC doses of 0, 50 or 300 IU kg-1 were administered. Thereafter, coagulation in an
arteriovenous (AV) shunt was evaluated and histopathologic examination for thrombotic changes performed.
Venous thrombosis was also assessed in a modiﬁed Wessler model.
Results:At the suprapharmacologic dose of 300 IU kg-1, PCC increased thrombusweight duringAV shunting, but this
effect could be prevented by dabigatran at all tested doses. AV shunt occlusion after PCC administrationwas delayed
by 75 μg kg-1 dabigatran and abolished by progressively higher dabigatran doses. High-dose treatment with
300 IU kg-1 PCC resulted in histologically evident low-grade pulmonary thrombi; however, that effect could be
blocked by dabigatran in a dose-dependentmanner (p= 0.034). In rabbits treatedwith high-dose PCC, dabigatran
inhibited thrombus formation during venous stasis. PCC effectively reversed dabigatran-induced bleeding.
Conclusions: In this animal study, thrombosis after PCC administration could be prevented in the presence
of dabigatran. PCC reversed dabigatran-induced excessive bleedingwhile retaining protective anticoagulatory activ-
ity of dabigatran.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
New oral anticoagulants such as the direct thrombin inhibitor (DTI)
dabigatran etexilate and the direct factor Xa inhibitors rivaroxaban,
apixaban and edoxaban have expanded clinical options, simpliﬁed
dosing and eliminated the need for routine monitoring in patients at
risk of stroke and thromboembolism when compared to the traditional
anticoagulants. However, all anticoagulation agents carry the risk of
bleeding, and this risk appears to be increased in patients with renal
dysfunction or advanced age. Even though the new anticoagulants
have relatively short half-lives, rapid reversal remains necessary innnual Meeting of the Society
any, February 20-23, 2013 and
Thrombosis and Haemostasis,
gy and Toxicology, CSL Behring
, Germany. Tel.: +49 6421 39
g).
. This is an open access article underpatientswithmajor bleeding requiring emergency treatment, suspected
overdose or need of an urgent invasive procedure [1].
Speciﬁc agents that can reverse the actions of dabigatran etexilate
and other new oral anticoagulants are still not available [2]. Non-
speciﬁc pro-hemostatic agents such as prothrombin complex concen-
trates (PCCs), activated PCCs and recombinant factor VIIa may be able
to circumvent the action of the direct inhibitors, but more research on
their efﬁcacy and safety is still needed.
PCCs have proven to be highly effective in urgent reversal of couma-
rin anticoagulation and are currently recommended as the preferred re-
versal agent for coumarin-associated bleeding in American and British
guidelines [3–5]. In a prospective multinational clinical trial, the PCC
Beriplex® P/N (CSL Behring GmbH, Marburg, Germany) rapidly and ef-
fectively reversed the anticoagulant activity of all three commercially
available coumarins, i.e. acenocoumarol, phenprocoumon andwarfarin,
in patients requiring emergency interventions or experiencing acute
bleeding [4].
Evidence on PCC reversal of the new oral anticoagulants is still
almost exclusively limited to in vitro experiments and studies in animalsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
730 E. Herzog et al. / Thrombosis Research 134 (2014) 729–736or normal human volunteers [6–12]. In healthy volunteers receiving
standard oral dabigatran extexilate doses of 150 mg twice daily, one
PCC (Cofact®, Sanquin Blood Supply, Amsterdam, the Netherlands)
could not reverse the prolongation of activated partial thromboplastin
time, ecarin clotting time or thrombin time [7]. However, in that
study the administered dabigatran doses were unlikely to pose in-
creased bleeding risk, and the measured coagulation parameters
have not been validated for assessing dabigatran-induced bleeding
diathesis and its reversal by PCC. In our recently published study of
rabbits undergoing a standardized kidney incision after high doses of
dabigatran, Beriplex P/N at a dose comparable to that used clinically
fully normalized blood loss and thus showed promise for dabigatran
reversal [12].
Rapid reversal of anticoagulants carries its own risk. Like other
procoagulant agents, PCCs have the potential for thrombotic adverse
events, although the reported risk has been low [5,13]. Nevertheless,
this potential risk is of particular relevance in the thrombosis prone
population for whom the new oral anticoagulants are typically pre-
scribed. The present study was designed to investigate the risk of
thrombosis associated with administration of Beriplex P/N to reverse
dabigatran-induced excessive bleeding in a rabbit model. The effective-
ness of anticoagulation and occurrence of thrombotic events were
assessed in an arteriovenous (AV) shunt. Thrombus formation was
also evaluated by histological examination and in a modiﬁed Wessler
model of venous stasis. The effects of Beriplex P/N on blood loss, time
to hemostasis and coagulation parameters were also determined to
conﬁrm effective anticoagulation reversal under the conditions of the
study.
Materials and Methods
Study Design
This open-label, placebo-controlled studywas designed to assess the
thrombotic safety of PCC for reversing the effects of dabigatran in a rab-
bit model. The study design is outlined in Fig. 1. The primary endpoint
was time to thrombotic occlusion of an AV shunt. Secondary endpoints
were thrombuswetweight in the AV shunt; development of pulmonary
thrombi; thrombosis score and thrombus weight after venous stasis;
levels of the surrogate thrombogenicity markers D-dimer, thrombin-15 40 530
Time (m
50 or 300
IU kg PCC-1
Dabigatran Bolus + Co
AV Shunt
Fig. 1. Study design. Abbreviations: AV, arteriovenantithrombin complex and prothrombin activation fragments 1 + 2;
blood loss; time to hemostasis; and peak thrombin generation.
Animals
Female CHB rabbits 3-4 months old weighing 2.8-3.3 kg (Bauer,
Neuental, Germany) received care in compliancewith the EuropeanCon-
vention on Animal Care, and the study was approved by the local Ethics
Committee. The animals were housed individually in wire-steel cages at
21-23 °C and 50% relative humidity under a 12 h/12 h light-darkness
cycle and provided tap water and rabbit food pellets (Deukanin®,
Deutsche Tiernahrung Cremer GmbH & Co. KG, Duesseldorf, Germany)
ad libitum.
Anesthesia
As previously described [12,14], anesthesia was induced with
5 mg kg-1 iv ketamine (Ketavet®, Pharmacia GmbH, Erlangen,
Germany) and 0.5 mg kg-1 iv xylazine 2% (Rompun®, Bayer Vital
GmbH, Leverkusen, Germany) and maintained with isoﬂurane
(Isoﬂuran CP®, CP-Pharma Handelsgesellschaft mbH, Burgdorf,
Germany). After a 20 min stabilization period, a carotid artery catheter
was used to measure hemodynamic, coagulation and hematological
parameters.
Treatments
Test agents were administered via an ear vein. Groups of 5 rabbits
each were randomly allocated to each study treatment for assessment
of AV shunt thrombus formation, bleeding and histopathology. At base-
line, bolus doses of 0 (isotonic saline), 75, 200 or 450 μg kg-1 dabigatran
(Boehringer Ingelheim Pharma GmbH, Ingelheim, Germany) were ad-
ministered followed over the 90min experimental period by continuous
dabigatran infusions of 0, 180, 450 and 900 μg kg-1 h-1, respectively. The
continuous infusions were intended to maintain plasma dabigatran
levels throughout the experiment comparable to those produced by
the initial boluses. Although dabigatran was administered both by
boluses and continuous infusions, in this report the groups are desig-
nated for conciseness according to the size of the bolus doses. At
15 min, 0 (isotonic saline), 50 or 300 IU kg-1 PCC was administered.60 75 90
in)
ntinuous Infusion
Bleeding from
Kidney Incision
ous; PCC, prothrombin complex concentrate.
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Starting 5 min after PCC administration, an AV shunt was created by
redirecting blood ﬂow from the left carotid artery to the right external
jugular vein via ﬂexible tubing and an in-line 16 × 7 mm glass chamber
(Fig. 1). Bloodﬂow through the shuntwasmonitored using a Transonic®
ﬂow meter (Transonic Systems Inc., Ithaca, New York, USA). Shunting
was continued for 30 min. Time to thrombotic occlusion was recorded
as the interval from shunt opening at 20min after the start of the exper-
iment until either blood ﬂow cessation or expiration of the shunting pe-
riod (Fig. 1). Thrombuswetweight in the shuntwasmeasured at the end
of the 30 minute shunting period.
Kidney Incision
At 10 min after the completion of AV shunting, a standardized
15 mm long and 5 mm deep scalpel incision was created at the lateral
kidney pole (Fig. 1), as elsewhere detailed [12]. Blood loss, i.e. the
volume of blood collected from the kidney incision site with a syringe,
and time to hemostasis were determined over the 30min period begin-
ning immediately after the incision. Time to hemostasis was deﬁned
as the interval elapsed from the kidney incision until cessation of ob-
servable bleeding or oozing.
Laboratory Assays
Blood samples were collected at baseline and 15, 20, 60 and 90 min.
D-dimer was determined with a clinical chemistry analyzer (Cobas®
111, Roche Diagnostics, Mannheim, Germany). Thrombin-antithrombin
complex and prothrombin activation fragments 1 + 2 were measured
by enzyme linked immunosorbent assays (Cusabio®, Hölzl Diagnostika,
Köln, Germany). Plasma dabigatran concentration was quantiﬁed
by Hemoclot Thrombin Inhibitor (HTI) assay (Hyphen BioMed,
Neuville-Sur-Oise, France) [15]. Calibrated automated thrombinography
(CAT, Thrombinoscope B.V., Maastricht, the Netherlands) and the
Thrombinoscope software version 3.0.0.29 were used to measure peak
thrombin generation in diluted platelet-poor plasma samples with re-
spective recombinant relipidated tissue factor and phospholipid concen-
trations of 5 pM and 4 μM [16]. Prothrombin time (PT) and diluted PT
(dPT) were measured with a Schnitger & Gross coagulometer (Heinrich
AmelungGmbH, Lemgo, Germany) and, respectively, the Thromborel® S
(Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany)
and 1:256 diluted Neoplastine® R reagents (Stago Deutschland GmbH;
Düsseldorf, Germany).
Histopathology
At the end of the experiment lung, kidney, heart, and brain tissue
were harvested, ﬁxed in 10% neutral buffered formalin and stained
with hematoxylin and eosin. Histopathological examination of the tis-
sue specimens was performed by Covance Laboratories Ltd., North
Yorkshire, UK. Any observed thrombi were classiﬁed on a grade of 1 to
5 from minimal to severe.
Modﬁed Wessler Model
In separate experiments, venous stasis was investigated using the
Wessler rabbit model [17] as modiﬁed by Giles et al. [18]. Five animals
per group each were randomly allocated to receive 200 IU kg-1 PCC
alone or followed by 200 μg kg-1 dabigatran and 3 animals each to
negative control treatmentwith isotonic saline or positive control treat-
ment with 50 U kg-1 FEIBA® NF 500 E (Factor Eight Inhibitor Bypass
Activity, Baxter Deutschland GmbH, Unterschleißheim, Germany). The
200 IU kg-1 PCC dose was selected for the venous stasis model on
the basis of preliminary dose-ranging experiments (data not shown).
In those experiments, there was no evidence of thrombosis at the50 IU kg-1 PCC dose, whereas 200 IU kg-1 PCC produced an approxi-
mately half-maximal thrombosis response.
After induction of anaesthesia, a jugular veinwas exposed and a seg-
ment of 2 cm isolated. Side brancheswere occluded using titaniumclips.
Test ﬂuids were then infused i.v. via the contralateral ear vein.
Ten min after the end of the infusion, a ligature was placed around
the isolated jugular vein. After the vein segment ﬁlled with blood, a
second ligature was placed 1.5 cm cranial to the ﬁrst, resulting in com-
plete stasis within the isolated segment. Twenty min after stasis induc-
tion, the vein segment was excised and dissected in sodium citrate
solution. Thrombosis scores were assigned to the jugular vein segment
contents on a scale from 0 to 3: 0 for no clot; 1 for one clot or several
small clots too small to weigh; 2 for one or more non-occlusive clots;
and3 for a fully occlusive clot. Thrombuswetweightwas alsomeasured.
Statistical Analysis
Times to thrombosis and hemostasis were analyzed by Cox propor-
tional hazards regression. Dabigatran dose-related changes in incidence
of pulmonary thrombi were evaluated by logistic regression. Thrombo-
sis score, thrombus weight and blood loss differences were determined
by exactWilcoxon test. PCC dose-dependent changes in peak thrombin
generation were assessed by linear regression. R version 2.15.2 statisti-
cal software (The R Foundation for Statistical Computing, Vienna,
Austria) was used for all analyses.
Results
Plasma Dabigatran
By 15 min after the start of treatment with 75, 200 or 450 μg kg-1
dabigatran boluses, geometric mean plasma dabigatran concentrations
(geometric coefﬁcient of variation) were 164 (128), 579 (53) or 1016
(25) ng mL-1, respectively. Mean plasma dabigatran concentrations
remained at approximately those levels or higher throughout the rest
of the experiment.
Thrombosis
The AV shunt rapidly occluded in 4 of 5 control animals receiving
neither PCC nor dabigatran and all those receiving PCC without
dabigatran (Fig. 2). While the time to thrombotic occlusion was slightly
shortened by PCCwithout dabigatran present, this effect was not signif-
icant (p = 0.30 for the 50 IU kg-1 PCC dose and p = 0.072 for the
300 IU kg-1 PCC dose). Upon treatment with 75 μg kg-1 dabigatran, AV
shunt occlusion in PCC-treated rabbits was delayed and with progres-
sively higher dabigatran doses fully abolished.
In the absence of dabigatran, thrombus weight after AV shunting
was increased (p = 0.008) from a median of 94 mg to 166 mg by
the 300 IU kg-1 PCC dose (Fig. 3). The increase did not persist in the
presence of dabigatran at any dose. Regardless of PCC dose, thrombus
was measurable in only two animals receiving 200 μg kg-1 dabigatran
and none receiving 450 μg kg-1.
At 90 min D-dimer levels increased to a median of 1.53 ﬁbrinogen
equivalent units (FEU) per mL (range, 0.42-10.2 FEU mL-1) in rabbits
treated with 300 IU kg-1 PCC but no concomitant dabigatran, as com-
pared with only 0.18 FEU mL-1 (range, 0.14-0.25 FEU mL-1) at the
50 IU kg-1 PCC dose. At that time point a single rabbit treated with
300 IU kg-1 PCC plus 75 μg kg-1 dabigatran showed a minor D-dimer
increase to 0.40 FEU mL-1. Otherwise no increases in D-dimer were ob-
served. No changes were detected in thrombin-antithrombin complex
or prothrombin activation fragments 1 + 2.
Since, even in the absence of dabigatran, the 50 IU kg-1 PCC dose
neither signiﬁcantly accelerated thrombotic occlusion (Fig. 2) nor
signiﬁcantly increased thrombus weight (Fig. 3), no histopathological
examination to detect the presence of thrombi was performed in
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(minimal) pulmonary thrombi were found in all rabbits treated
with 300 IU kg-1 PCC alone. A grade 1 heart thrombus was also noted
in one animal of that group. The frequency of pulmonary thrombi
declined progressively with increasing concomitant dabigatran dose
(p = 0.034), as shown in Fig. 4. At the 450 μg kg-1 concomitant
dabigatran bolus dose, no animal developed pulmonary thrombi.
In the venous stasis model, no clotting was observed after isotonic
saline infusion, whereas fully occlusive clots formed after FEIBA treat-
ment (Fig. 5). Small or non-occlusive clots developed after treatment
with 200 IU kg-1 PCC alone. Dabigatran co-administration prevented
clotting in 4 of 5 PCC-treated rabbits (p = 0.024).
Coagulation Time
At 90 min, increasing dabigatran doses progressively prolonged dPT
and PT (Table 1). The effects of either 50 or 300 IU kg-1 PCC on this pro-
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Fig. 3. Thrombus weight after AV shunting in individual rabbits treated with 0, 50 or 300 IU kg
Abbreviation: PCC, prothrombin complex concentrate.Blood Loss
In the control group receiving isotonic saline but no dabigatran or
PCC, blood loss during the 30 min period after kidney incision ranged
from 0.5 to 3.0 mL (Fig. 6). Dabigatran doses of 200 and 450 μg kg-1
markedly increased blood loss to median volumes of 51 mL (range,
28-64 mL) and 56 mL (range, 46-78 mL), respectively. Treatment with
either 50 or 300 IU kg-1 PCC attenuated the blood loss increase resulting
from 200 μg kg-1 dabigatran (p= 0.008). The 300 IU kg-1 PCC dosewas
also effective in diminishing the increase produced by 450 μg kg-1
dabigatran (p = 0.048).
Time to Hemostasis
Bleeding cessation was attained within 2-4 min following kidney
incision in the control group receiving isotonic saline without either
dabigatran or PCC (Fig. 7). A bolus of 75 μg kg-1 dabigatran showed
no effect on time to hemostasis. By contrast, in the absence of PCC all200 450
n Dose ( g kg )-1
PCC Dose
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µ
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bleed throughout the 30 min observation period. In animals treated
with 200 μg kg-1 dabigatran, increasing PCC doses shortened time to
hemostasis (p b 0.01). Neither 50 nor 300 IU kg-1 PCC could reverse
the effects of 450 μg kg-1 on time to hemostasis.
Thrombin Generation
Mean (±standard deviation) peak thrombin generation at
60 min was comparable in rabbits receiving isotonic saline alone
(135 ± 33 nM) or 75 μg kg-1 dabigatran alone (106 ± 30 nM). After
200 μg kg-1 dabigatran alone, however, peak thrombin generation was
markedly reduced (Fig. 8). A linear dose-response relationship was
observed between PCC dose and thrombin generation (p b 0.001).
Whereas 50 IU kg-1 PCC normalized peak thrombin generation after
200 μg kg-1 dabigatran, 300 IU kg-1 increased it to supraphysiologic
levels (Fig. 8). PCC at a dose 300 IU kg-1 was even effective in over-
coming 450 μg kg-1 dabigatran, with mean peak thrombin generation
increasing to 408 ± 59 nM.
Despite normalization of peak thrombin generation by 50 IU kg-1
PCC in animals receiving 200 μg kg-1 dabigatran (Fig. 8), hemostasis
was only partially restored in that group (Fig. 7). It has previously
been demonstrated that PCC can normalize peak thrombin generation
at doses lower than those needed to reverse fully the anti-hemostatic
effects of dabigatran [12].
Discussion
This rabbit model study adds to the evidence that PCCs can effective-
ly and rapidly accomplish emergency reversal of DTI-induced bleeding.
Dabigatran blocked thrombotic occlusion of an externalized AV shunt
following a bolus of PCC. These ﬁndings indicate the feasibility of PCC
treatment to avoid bleeding with reduced thrombotic risk due to the
persistence of DTI in the plasma.
The AV shunt presents a thrombogenic surface, thus serving to the
mimic the heightened thrombotic risk of patients receiving DTI therapy.
AV shunt thrombosis is classiﬁed as a mixed model, in that thrombus
formation depends both on platelet activation and the coagulation cas-
cade [19]. In the rabbit, the AV shunt has been validated for assessing
the antithrombotic activity of DTIs [20], heparin [20–23], inhibitors
of factor Xa [21,24] and XIIa [22,23], and vitamin K antagonists [24].
Responses in this model are directly proportional to dose and the in-
hibitory constant of the test agent [20,21,24].
After 50 IU kg-1 PCC, the maximum recommended clinical dose, no
increased thrombosis was observed during AV shunting in dabigatran-treated animals. At the suprapharmacologic PCC dose of 300 IU kg-1,
higher dabigatran doses progressively retarded shunt thrombosis.
That high dosewas selected in order to increase the likelihood of throm-
boembolic events and so characterize PCC thrombotic safety margin.
In our earlier study using thismodel, 50 IU kg-1 Beriplex P/Nnormal-
ized blood loss in all individual rabbits who had received a bolus dose of
400 μg kg-1 dabigatran [12]. The design of the present study differs in
several respects but nevertheless complements the previous investiga-
tion. In the current study, a dose of PCC 6 times the maximum recom-
mended dose was tested, and a dabigatran bolus was followed by a
continuous infusion in order tomaintain high levels of the anticoagulant
comparable to those following oral dabigatran dosing in patients. In
atrial ﬁbrillation patients receiving standard oral dosing with 150 mg
dabigatran etexilate bid, geometric mean plasma dabigatran concentra-
tions have been reported to vary from a post-dose peak of 175 ng mL-1
to a trough of 91 ng mL-1 at 12 h thereafter [25]. Furthermore, in
10% of patients receiving either 110 or 150 mg dabigatran etexilate
Table 1
dPT and PT⁎.
Dose Median (Range)
Dabigatran (μg kg-1) PCC (IU kg-1) dPT (sec) PT (sec)
0 0 26 (22-31) 10 (9-11)
75 0 51 (26-70) 10 (8-12)
200 0 89 (24-178) 14 (9-30)
450 0 99 (20-242) 18 (8-35)
0 50 43 (32-62) 9 (8-10)
75 50 96 (50-165) 11 (10-13)
200 50 101 (23-227) 13 (10-18)
450 50 138 (26-243) 17 (10-28)
0 300 28 (22-33) 9 (8-13)
75 300 50 (22-90) 10 (8-15)
200 300 93 (26-164) 13 (9-18)
450 300 160 (31-294) 16 (10-23)
⁎Measured at 90 min.
Abbreviations: dPT, diluted prothrombin time; PCC, prothrombin complex concentrate;
PT, prothrombin time.
734 E. Herzog et al. / Thrombosis Research 134 (2014) 729–736bid and experiencing major bleeding, trough dabigatran levels were
≥ 269 ng mL-1 [25]. In the present study, geometric mean plasma
dabigatran concentration among rabbits receiving the 75 μg kg-1 dose
was 164 ngmL-1, a level comparable to that in atrial ﬁbrillation patients
receiving standard dosing. In contrast, the 200 and 450 μg kg-1
dabigatran doses in the rabbits produced high geometric mean plasma
levels of 579 and 1016 ng mL-1, respectively, which were associated
with bleeding.
Results with the venous stasis model, which allows thrombi to form
in the presence of endothelial cell surfaces without contacting artiﬁcial
materials, supported those in the AV shunt model. Thrombus formation
during stasis after high-dose PCC treatment could be inhibited by
dabigatran co-administration.
All prothrombotic agents have the potential to produce thromboem-
bolic adverse events. However, after more than 15 years of clinical use,
the reported risk of thromboembolic events with Beriplex P/N has been
low [3,5,13].Most recently, after an estimated total of almost 650000 in-
fusions, only 21 thromboembolic events judged possibly related to
Beriplex P/Nwere either published in the scientiﬁc literature or sponta-
neously reported through a pharmacovigilance program [13]. More-
over, much of that use has been in patients with non-valvular atrial
ﬁbrillation, who are at increased risk of thrombotic events and consti-
tute the same population as that receiving DTI therapy.0 75
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Abbreviation: PCC, prothrombin complex concentrate.Dabigatran competitively inhibits both free and clot-bound throm-
bin by binding to the active site, and the inhibition is rapid and revers-
ible [26]. The mechanisms by which PCCs can non-speciﬁcally reverse
the anticoagulant activity of dabigatran have not been fully explored.
The additional coagulation factors provided by PCC appear sufﬁcient
to overcome the blockade by dabigatran, thus allowing the coagulation
cascade to proceed to completion.
Prothrombin accumulation associated with repeated doses of PCCs
may be the primary determinant of thrombotic risk [5,27]. Consequent-
ly, in the reversal of DTIs the prothrombin component of PCCs appears
to be both a keymediator of efﬁcacy and potential source of thrombotic
risk.
PCCs contain both procoagulant and anticoagulant constituents
to increase their margin of safety. In addition to the four coagulation
factors II, VII, IX and X, Beriplex P/N also contains the anticoagulant
proteins C, S and Z, as well as antithrombin and heparin [28]. These
anticoagulants in conjunction with remaining dabigatran may limit
the thrombogenic potential of PCC used for dabigatran reversal.
The degree of dabigatran reversal possible using currently recom-
mended PCC doses is expected to be at least partly inﬂuenced by the
plasma concentration of dabigatran in the patient at the time of treat-
ment. PCC may be of limited effectiveness in the face of very high
dabigatran levels. In human plasma samples containing dabigatran at
concentrations 4-8 fold greater than therapeutic levels, the addition of
PCC could not restore normal endogenous thrombin potential [8]. In
our previous study, Beriplex P/N at doses comparable to those for
routine clinical use reversed the effects of plasma dabigatran concentra-
tions corresponding to those present in patients under dabigatran treat-
ment [12,29,30].
Rabbitsmodels are well established in experimental hemostasis and
thrombosis [14,31–34]. In order to minimize uncertainty about the ap-
plicability of the present model to clinical DTI reversal, dabigatran was
infused intravenously in its active form rather than administered orally
as the prodrug dabigatran etexilate. Thus, possible species-related dif-
ferences in drug absorption and conversion to active form cannot have
inﬂuenced the present data.
Beriplex P/N has also been shown to provide an effective antidote to
dabigatran in a murine model of intracranial hemorrhage exacerbation
by oral anticoagulant [9]. That PCC and, less consistently, fresh-frozen
plasma prevented excess hematoma expansion caused by dabigatran
etexilate, whereas recombinant human factor VIIa was ineffective. Pre-
vention of hematoma growth and reversal of tail vein bleeding time
by PCC were dose-dependent. In a rat tail bleeding model, bleedingp = 0.008
p = 0.008
p = 0.048
200 450
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735E. Herzog et al. / Thrombosis Research 134 (2014) 729–736time was normalized by 35 IU kg-1 Beriplex P/N at the earliest moni-
toring time 5 minutes after tail incision [8].
Data on the use of PCCs in humans as an antidote to dabigatran
remain limited. Three studies have tested PCCs as a dabigatran antidote
in healthy volunteers [7,11,35]. In one of the studies, volunteers
who had taken oral doses of dabigatran were administered a PCC anti-
dote [7], whereas in the other two studies antidotes were tested
in vitro using blood sample from volunteers [11,35]. Studies in healthyPe
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CI, 95% conﬁdence interval; PCC, prothrombin complex concentrate.volunteers pose difﬁculties, since it is not ethical to administer high
dabigatran doses associated with increased bleeding risk. All three
studies relied on surrogate coagulation markers to assess effectiveness.
PCCs appeared to correct some parameters partially but not others. The
suitability of such markers for evaluating dabigatran-induced bleeding
diathesis and its reversal by PCC remains unclear. In the animal studies,
surrogate coagulationmarkers have in general been poorly predictive of
bleeding cessation.
In patients, case reports have appeared of successful emergency
dabigatran reversal by 3-factor [36] and 4-factor [37,38] PCC and
activated PCC [39]. Further studies are much needed. However, since
dabigatran-related bleeding events are rare, conducting an adequately
powered clinical trial in patients presents a challenge.
The present rabbit model study conﬁrms that PCC can rapidly re-
verse dabigatran overdose. The study also provides the ﬁrst assessment
of thromboembolic risk associated with PCC administration for
dabigatran reversal. That risk appears to be constrained both by residual
dabigatran and the composition of Beriplex P/N.
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